Oncothyreon, Inc. (NASDAQ: ONTY), a biotechnology company, is committed to the development of oncology products designed to improve the lives and outcomes of cancer patients. Currently, the company is in the process of developing multiple therapeutic candidates targeting cancer in specific and effective ways. With headquarters in Seattle, Washington, their pipeline includes both synthetic vaccines and small molecules for a variety of cancer indications. For further information, visit the Company’s web site at www.oncothyreon.com.
- 17 years ago
QualityStocks
Oncothyreon, Inc. (NASDAQ: ONTY)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Narrows Q2 Loss 66% as E-Commerce Growth Offsets Healthcare Headwinds
NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company in healthcare and technology,…
-
QualityStocksNewsBreaks – Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) Stands Distinct Against Walker Lane Backdrop
Lahontan Gold (TSX.V: LG) (OTCQB: LGCXF) is positioned as investors view the Walker Lane corridor in…
-
QualityStocksNewsBreaks – Solowin Holdings (NASDAQ: SWIN) Targets $1 Billion AUM for Tokenized USD Money Market Product by Year-End 2025
Solowin (NASDAQ: SWIN), a financial services firm bridging traditional and digital assets, announced an initiative…